Pulmonary and Total Blood Volume in COPD
NCT07428785
Summary
Background Patients with chronic obstructive lung disease (COPD) suffer from a progressive loss of lung function that leads to poor quality of life, and often invalidity and early death. This is markedly affected by a reduced exercise capacity and dyspnoea, but the underlying mechanisms are unknown. In the present study, we aim to investigate whether this may involve a reduced pulmonary blood volume secondarily to a reduced total blood volume. Methods Design: Prospective matched comparative study Intervention: None Outcomes: The primary outcome is pulmonary blood volume estimated to total blood volume ratio between patients with COPD and healthy controls individually matched for age, sex, and height. Statistical design: All statistical analyses will be performed using R statistical software version 4.1.1 (R Project for Statistical Computing) within RStudio statistical software version 1.4.1717 (RStudio), and a two-tailed p\<0.05 will be considered statistically significant. Inspection of normality and variance homogeneity will be done by creating qq-plots and histogram. Regulatory considerations: This study will be submitted for approval by Regional Ethical Committee. Perspective: This study will help uncover fundamental aspects of the pathophysiology of COPD.
Eligibility
Inclusion Criteria: * Inclusion criteria -patients * Men and women * 45-80 years * COPD (GOLD stage I to III) * Resting arterial oxygenation \> 90% Inclusion criteria - controls * Men and women * 45-80 years * Normal FEV1, FVC, FEV1/FVC, and single-breath diffusion capacity * Same sex, age (± 3 years) and height (± 5 cm) as an included COPD patient * Low- to moderate activity level defined as \< 1,5 hours of structured physical activity pr. week at moderate intensity and cycling \< 30 minutes/5km pr. day at moderate intensity (moderate intensity = out of breath but able to speak) Exclusion Criteria: Exclusion criteria - patients * Symptoms of ischaemic heart disease * Known heart failure * Previous severe or current COVID-19 * Claudication * Symptoms of disease within 2 weeks prior to the study * Participation in pulmonary rehabilitation within 6 months * Known malignant disease * Pregnancy * Unstable cardiac arrhythmic disease * Renal or liver dysfunction Exclusion criteria - controls * Known chronic lung disease * Known ischaemic heart disease * Known heart failure * Previous severe or current COVID-19 * Symptoms of disease within 2 weeks prior to the study * Known malignant disease * Claudication * Pregnancy * Unstable cardiac arrhythmic disease * Renal or liver dysfunction
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07428785